Hims & Hers Health (HIMS) Insider Cosgrove Buys 3,656 Shares

Delos Cosgrove purchased 3,656 shares of Hims & Hers Health, Inc. (HIMS) on June 11, 2026. This transaction was disclosed in a recent regulatory filing with the SEC and occurred as the stock traded near $26.82. The acquisition adds to the insider activity at the San Francisco-based health and wellness platform, which has seen several executives and directors adjusting their positions throughout the month.

Recent Insider Activity at Hims & Hers

The move by Cosgrove is part of a broader pattern of insider trades this June. On the same day as Cosgrove's purchase, David Wells also acquired 3,656 shares. Just a few days later, on June 15, 2026, CTO Mohamed Elshenawy added 282,597 shares to his holdings. Not all recent moves have been buys, however. Chief Policy Officer Deborah Autor sold 15,396 shares on June 15, 2026, at a price of $30.17. More recently, Chief Legal Officer Soleil Boughton sold 3,461 shares on October 14, 2026, at an average price of $29.06 per share under a pre-arranged trading plan. This followed a larger disposal by Boughton of 42,261 shares back in mid-June.

Stock Performance and Market Position

Hims & Hers shares have experienced significant volatility over the past year. The stock has traded as high as $57.45 and as low as $13.74. Currently, the price sits slightly below its 50-day moving average of $29.40 and its 200-day moving average of $27.32. With a market capitalization of approximately $6.85 billion, the company is valued at a forward P/E ratio of 39.85, which measures its current share price against its predicted earnings per share.

Revenue Growth and Financial Results

In its most recent financial reporting, Hims & Hers showed a revenue growth rate of 38.2%, bringing total revenue to $2.58 billion. While the company is growing its top line quickly, it has not yet reached profitability, reporting a negative return on equity of 32.03%. The company's next earnings report is scheduled for November 9, 2026, where the market will look for updates on its margins and the scaling of its newer weight loss and dermatology categories.

Analysts Set New Price Targets

Financial analysts have issued a variety of outlooks for Hims & Hers in recent months. On August 24, 2026, Truist Securities kept a Hold rating but lifted its price target to $32.00 from $27.00. Earlier in August, Needham maintained a Buy rating and set a price target of $42.00, while Barclays reiterated an Overweight rating with a $35.00 target. Other firms, including Citigroup and Deutsche Bank, maintain Neutral or Hold ratings with price targets between $26.00 and $33.00. Across 13 analyst opinions, the stock carries a consensus Hold recommendation.

About Hims & Hers Health, Inc.

Hims & Hers Health operates a digital platform that connects patients with licensed healthcare providers for various treatments. The company focuses on sensitive health areas like hair loss, sexual health, skincare, and mental health, selling both prescription and over-the-counter products directly to consumers. By moving into categories like weight loss and hormone health, the company is trying to become a one-stop shop for personalized wellness.

What's Ahead for Hims & Hers Health, Inc.

While insider buying can sometimes be seen as a sign of internal confidence, these filings are backward-looking and do not necessarily reflect current sentiment or future stock performance. Investors will likely focus on the November 9 earnings date to see if the company can turn its high revenue growth into consistent profits. The recent cluster of trades in June and the varying analyst targets suggest the market is still weighing the company's long-term valuation against its rapid expansion.